Randomized Efficacy and Safety Trial With Oral S 44819 After Recent Ischemic Cerebral Event. International, Multi-centre, Randomized, Doubleblind Placebo-controlled Phase II Study. (RESTORE BRAIN Study)
Latest Information Update: 05 Apr 2022
Price :
$35 *
At a glance
- Drugs Afizagabar (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms RESTORE BRAIN
- Sponsors Servier
- 03 Feb 2020 Trial design published in the Trials
- 04 Apr 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 This trial has been completed in Hungary.